Literature DB >> 33639844

CDX2 and Reg IV expression and correlation in gastric cancer.

Dandan Chai1, Huifen Du1, Kesheng Li2, Xueliang Zhang3, Xiaoqin Li4, Xiaoning Zhao5, Xiaowen Lian1, Yang Xu1.   

Abstract

BACKGROUND: Ectopic expression of CDX2 is associated with the development and progression of gastric cancer. Previous studies showed that CDX2 may be an upstream regulator of Reg IV expression in gastric cancer, and our previous report showed that Reg IV upregulated SOX9 expression and enhanced cell migration and invasion in gastric cancer cells. However, the regulatory roles of CDX2 have not been clarified in gastric cancer, and the correlation between CDX2 and Reg IV requires further study.
METHODS: CDX2 and Reg IV were examined in gastric cancer specimens and paired adjacent tissues via real-time PCR and immunohistochemistry (IHC). The association between CDX2 and Reg IV was assessed using the χ2-test and Spearman's rank correlation. To verify their relationship, knockdown and exogenous expression of CDX2 or Reg IV were performed in AGS and MKN-45 gastric cancer cells, and their expression was subsequently analyzed via a real-time PCR and western blotting. Wound-healing and Transwell assays were used to examine migration and invasion in AGS and MKN-45 cells following CDX2 silencing or overexpression.
RESULTS: A positive correlation was observed between CDX2 and Reg IV expression at the mRNA and protein levels in gastric cancer tissues. CDX2 silencing significantly downregulated Reg IV expression, and CDX2 overexpression significantly upregulated Reg IV expression in AGS and MKN-45 cells. Neither Reg IV silencing nor overexpression had any effect on CDX2 protein expression in AGS or MKN-45 cells, even though both affected the expression of CDX2 mRNA. Functionally, CDX2 silencing significantly inhibited cell migration and invasion, and CDX2 overexpression significantly promoted cell migration and invasion in AGS and MKN-45 cells.
CONCLUSIONS: Our findings demonstrate that CDX2 expression was positively correlated with that of Reg IV in gastric cancer, and CDX2 promoted cell migration and invasion through upregulation of Reg IV expression in AGS and MKN-45 cells.

Entities:  

Keywords:  CDX2; Correlation; Gastric cancer; Invasion; Migration; Reg IV

Mesh:

Substances:

Year:  2021        PMID: 33639844      PMCID: PMC7913228          DOI: 10.1186/s12876-021-01678-9

Source DB:  PubMed          Journal:  BMC Gastroenterol        ISSN: 1471-230X            Impact factor:   3.067


  48 in total

1.  Cdx2 Expression and Intestinal Metaplasia Induced by H. pylori Infection of Gastric Cells Is Regulated by NOD1-Mediated Innate Immune Responses.

Authors:  Naoki Asano; Akira Imatani; Tomohiro Watanabe; Jun Fushiya; Yutaka Kondo; Xiaoyi Jin; Nobuyuki Ara; Kaname Uno; Katsunori Iijima; Tomoyuki Koike; Warren Strober; Tooru Shimosegawa
Journal:  Cancer Res       Date:  2016-01-12       Impact factor: 12.701

2.  CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45.

Authors:  L H Dang; F Chen; S A Knock; E H Huang; J Feng; H D Appelman; D T Dang
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

3.  PTEN expression and suppression of proliferation are associated with Cdx2 overexpression in gastric cancer cells.

Authors:  Zhi-Gang Bai; Ying-Jiang Ye; Dan-Hua Shen; You-Yong Lu; Zhong-Tao Zhang; Shan Wang
Journal:  Int J Oncol       Date:  2013-03-28       Impact factor: 5.650

4.  Expression of the REG IV gene in ulcerative colitis.

Authors:  Apichart Nanakin; Hirokazu Fukui; Shigehiko Fujii; Akira Sekikawa; Naoki Kanda; Hiroshi Hisatsune; Hiroshi Seno; Yoshitaka Konda; Takahiro Fujimori; Tsutomu Chiba
Journal:  Lab Invest       Date:  2007-01-29       Impact factor: 5.662

5.  CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer.

Authors:  Motonobu Saito; Hirokazu Okayama; Katsuharu Saito; Jin Ando; Kensuke Kumamoto; Izumi Nakamura; Shinji Ohki; Yoshimasa Ishi; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

6.  A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.

Authors:  Jie Ge; Zhikang Chen; Shaobin Wu; Weijie Yuan; Bin Hu; Zihua Chen
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-03-19       Impact factor: 4.126

Review 7.  Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens.

Authors:  Wataru Yasui; Naohide Oue; Kazuhiro Sentani; Naoya Sakamoto; Junichi Motoshita
Journal:  Pathol Int       Date:  2009-03       Impact factor: 2.534

8.  CDX2 as a prognostic marker in gastric cancer.

Authors:  M A Masood; A Loya; M A Yusuf
Journal:  Acta Gastroenterol Belg       Date:  2016 Apr-Jun       Impact factor: 1.316

9.  HpSlyD inducing CDX2 and VIL1 expression mediated through TCTP protein may contribute to intestinal metaplasia in the stomach.

Authors:  Qiuping Li; Yanmei Zhu; Jun Liu; Xiuwen Yu; Moye Chen; Nannan Dong; Yuehua Gong; Yuan Yuan
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

10.  Expression of Reg IV and SOX9 and their correlation in human gastric cancer.

Authors:  Na Zhang; Dandan Chai; Huifen Du; Kesheng Li; Wenguang Xie; Xingwen Li; Rong Yang; Xiaowen Lian; Yang Xu
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

View more
  3 in total

1.  TTN-AS1 delivered by gastric cancer cell-derived exosome induces gastric cancer progression through in vivo and in vitro studies.

Authors:  Yu Wang; Rongke Jiang; Hongying Zhao; Feng Li; Yanfang Li; Mei Zhu
Journal:  Cell Biol Toxicol       Date:  2022-10-10       Impact factor: 6.819

2.  Immunohistochemical Expression of CDX2 in Gastric Carcinoma.

Authors:  Ahmed Avan Sardar; Jalal Ali Jalal; Kalthuma Salih Hamad Ameen
Journal:  Iran J Pathol       Date:  2022-03-08

Review 3.  REG4 promotes the proliferation and anti-apoptosis of cancer.

Authors:  Hua-Chuan Zheng; Hang Xue; Cong-Yu Zhang
Journal:  Front Cell Dev Biol       Date:  2022-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.